Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

Silexion Therapeutics Corp. SLXN revealed new preclinical results demonstrating the synergistic efficacy of its SIL-204, in combination with components of first-line chemotherapy for pancreatic cancer.

The additional preclinical data show that SIL-204 exhibits significant synergistic activity with 5-fluorouracil and irinotecan — two main components commonly used in pancreatic cancer treatments — when tested in human pancreatic tumor cell lines harboring KRAS G12D mutations, the most common mutation in pancreatic cancer.

Also Read: Silexion Investigational Pancreatic Cancer Treatment Shows Promise In Animal Studies

Synergistic activity was also observed with the chemotherapeutic agent gemcitabine.

• Synergistic activity was observed after the confluence of these tumor cell lines, reflecting how SIL-204 may enhance the effects of 5-fluorouracil and irinotecan when used together, as well as that of gemcitabine. 
• In preclinical models, combining 5-fluorouracil and irinotecan with SIL-204 led to a significant reduction in cancer cell confluence after about three days compared to treatment with the chemotherapy agents alone. 

Silexion is planning to initiate toxicology studies with SIL-204 within the upcoming months and to advance SIL-204 into Phase 2/3 clinical trials in the first half of 2026, focusing initially on locally advanced pancreatic cancer (LAPC).

In parallel, the company plans to initiate preclinical studies for SIL-204 in colorectal cancer models.

Concurrently, Silexion Therapeutics priced a public offering of 3.7 million shares and warrants to purchase up to 3.7 million shares at a combined price of $1.35 per share and accompanying warrant, with gross proceeds of $5 million.

SLXN Price Action: SLXN stock is down 42.96% at 89 cents at publication Thursday.

Read Next:

• Bank of America Q4 Earnings: $6.7 Billion Profit, $1.7 Billion In Investment banking fees, Forecasts Higher NII In 2025

Photo: Romix Image via Shutterstock